Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-κB activation

International Immunopharmacology

Volumn 8, Issue 3, 2008, Pages 379-389

  Li, Bin ^a   Zhang, Rong ^a   Li, Jun ^a   Zhang, Lezhi ^a   Ding, Guofu ^a   Luo, Ping ^a   He, Shengqi ^a   Dong, Yan ^a   Jiang, Weiwei ^a   Lu, Yongling ^a   Cao, Hongwei ^a   Zheng, Jiang ^a   Zhou, Hong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Artesunate; CpG ODN; Heat killed Escherichia coli; LPS; Proinflammatory cytokines; Sepsis; TLR4; TLR9

Indexed keywords

ACTIVATED PROTEIN C; ANTIMALARIAL AGENT; ARTESUNATE; BACTERIAL DNA; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DIHYDROARTEMISININ; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; CELL ACTIVATION; CELL LINE; CELL SURFACE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UMBILICAL VEIN;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BACTEREMIA; CELLS, CULTURED; ENDOTOXINS; ESCHERICHIA COLI INFECTIONS; FEMALE; INTERLEUKIN-6; MALE; MICE; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; SESQUITERPENES; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39149123815     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.10.024     Document Type: Article

References (39)

1. Pinner R.W., Teutsch S.M., Simonsen L., Klug L.A., Graber J.M., et al. Trends in infectious diseases mortality in the United States. Jama 275 (1996) 189-193
2. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
3. Sparwasser T., Miethke T., Lipford G., Borschert K., Hacker H., et al. Bacterial DNA causes septic shock. Nature 386 (1997) 336-337
4. Vincent J.L., Sun Q., and Dubois M.J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34 (2002) 1084-1093
5. Genfa L., Jiang Z., Hong Z., Yimin Z., Liangxi W., et al. The screening and isolation of an effective anti-endotoxin monomer from Radix Paeoniae Rubra using affinity biosensor technology. Int Immunopharmacol 5 (2005) 1007-1017
6. Wang J., Zhou H., Zheng J., Cheng J., Liu W., et al. The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob Agents Chemother 50 (2006) 2420-2427
7. He X.L., and Liu Z. Protection of artesunate on activation and injury of vascular endothelial cells induced by lipopolysaccharide. Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 1110-1113
8. Xu H., He Y., Yang X., Liang L., Zhan Z., et al. Anti-malarial agent artesunate inhibits TNF-{alpha}-induced production of proinflammatory cytokines via inhibition of NF-{kappa}B and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology 46 (2007) 920-926
9. Efferth T., Ramirez T., Gebhart E., and Halatsch M.E. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67 (2004) 1689-1700
10. Chen H.H., Zhou H.J., Wu G.D., and Lou X.E. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 71 (2004) 1-9
11. Xu J.H., and Zhang Y.P. Contragestational effects of dihydroartemisinin and artesunate. Yao Xue Xue Bao 31 (1996) 657-661
12. Itonaga I., Sabokbar A., Sun S.G., Kudo O., Danks L., et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 34 (2004) 57-64
13. Yibin G., Jiang Z., Hong Z., Gengfa L., Liangxi W., et al. A synthesized cationic tetradecapeptide from hornet venom kills bacteria and neutralizes lipopolysaccharide in vivo and in vitro. Biochem Pharmacol 70 (2005) 209-219
14. Jiang Z., Hong Z., Guo W., Xiaoyun G., Gengfa L., et al. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 4 (2004) 527-537
15. Fungladda W., Honrado E.R., Thimasarn K., Kitayaporn D., Karbwang J., et al. Compliance with artesunate and quinine +tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 76 Suppl 1 (1998) 59-66
16. Yi A.K., Tuetken R., Redford T., Waldschmidt M., Kirsch J., et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 160 (1998) 4755-4761
17. Hu Z., Sun S., and Zhou F. The binding of CpG-oligodeoxynucleotides to cell-surface and its immunostimulatory activity are modulated by extracellular acidic pH. Vaccine 21 (2003) 485-490
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
19. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164 (2001) 396-402
20. Yao Y.M., Redl H., Bahrami S., and Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 47 (1998) 201-210
21. McCoy S.L., Kurtz S.E., Hausman F.A., Trune D.R., Bennett R.M., et al. Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization. J Biol Chem 279 (2004) 17217-17223
22. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., et al. A toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
23. Leifer C.A., Kennedy M.N., Mazzoni A., Lee C., Kruhlak M.J., and Segal D.M. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 173 (2004) 1179-1183
24. Hong Z., Jiang Z., Liangxi W., Guofu D., Ping L., et al. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 4 (2004) 223-234
25. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162 (1999) 3749-3752
26. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167 (2001) 3555-3558
27. Naiki Y., Michelsen K.S., Zhang W., Chen S., Doherty T.M., and Arditi M. Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM-and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem 280 (2005) 5491-5495
28. Eicher S.D., McMunn K.A., Hammon H.M., and Donkin S.S. Toll-like receptors 2 and 4, and acute phase cytokine gene expression in dexamethasone and growth hormone treated dairy calves. Vet Immunol Immunopathol 98 (2004) 115-125
29. Bhattacharyya S., Brown D.E., Brewer J.A., Vogt S.K., and Muglia L.J. Macrophage glucocorticoid receptors regulate toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109 (2007) 4313-4319
30. Sprung C.L., Caralis P.V., Marcial E.H., Pierce M., Gelbard M.A., et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 311 (1984) 1137-1143
31. Zhang P., Chen X.M., Luo B.D., Tan Q., Zou F., et al. Effects of artesunate on CD14 and toll-like receptor 4 in peritoneal macrophages of mice with heat stroke endotoxemia]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 24 (2006) 226-228
32. Veerasubramanian P., Gosi P., Limsomwong C., and Walsh D.S. Artesunate and a major metabolite, dihydroartemisinin, diminish mitogen-induced lymphocyte proliferation and activation. Southeast Asian J Trop Med Public Health 37 (2006) 838-847
33. Lin P.Y., Feng Z.M., Pan J.Q., Zhang D., and Xiao L.Y. Effects of artesunate on immune function in mice. Zhongguo Yao Li Xue Bao 16 (1995) 441-444
34. Guha M., and Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 13 (2001) 85-94
35. Yi A.K., Yoon J.G., Hong S.C., Redford T.W., and Krieg A.M. Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappa B. Int Immunol 13 (2001) 1391-1404
36. Hacker H., Vabulas R.M., Takeuchi O., Hoshino K., Akira S., and Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 192 (2000) 595-600
37. An H., Xu H., Yu Y., Zhang M., Qi R., et al. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. Immunol Lett 81 (2002) 165-169
38. Efferth T., Marschall M., Wang X., Huong S.M., Hauber I., et al. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med 80 (2002) 233-242
39. Mirshafiey A., Saadat F., Attar M., Di Paola R., Sedaghat R., and Cuzzocrea S. Design of a new line in treatment of experimental rheumatoid arthritis by artesunate. Immunopharmacol Immunotoxicol 28 (2006) 397-410